株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
企業レポート

PharmaPoint:多発性硬化症(MS) - 現在/将来の市場参入企業

PharmaPoint: Multiple Sclerosis - Current and Future Players

発行 GlobalData 商品コード 267071
出版日 ページ情報 英文 55 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
PharmaPoint:多発性硬化症(MS) - 現在/将来の市場参入企業 PharmaPoint: Multiple Sclerosis - Current and Future Players
出版日: 2013年03月31日 ページ情報: 英文 55 Pages
概要

当レポートでは、多発性硬化症(MS)市場で急成長を遂げている企業について調査分析し、主要企業の現状と促進要因に焦点を当てて、MSの競合情勢、主要企業プロファイルなどを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 市場の見通し

  • 世界市場
    • 予測
    • 促進要因・障壁

第4章 現在/将来の企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • Biogen Idec
    • Teva Pharmaceutical Industries
    • Merck Serono (EMD Serono)
    • Sanofi
    • Bayer HealthCare Pharmaceuticals
    • Novartis International
    • Hoffmann-La Roche
    • GlaxoSmithKline

第5章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC1009FPR

Abstract

PharmaPoint: Multiple Sclerosis - Current and Future Players

Summary

GlobalData has released its pharma report, "PharmaPoint: Multiple Sclerosis - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Multiple Sclerosis Market. The report identifies and analyses the key companies shaping and driving the global Multiple Sclerosis market. The report provides insight into the competitive Multiple Sclerosis landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Multiple Sclerosis
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of the Multiple Sclerosis sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving the Multiple Sclerosis Market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Multiple Sclerosis market landscape? Identify, understand and capitalize

TOC

1 Table of Contents

1 Table of Contents 5

  • 1.1 List of Tables 7
  • 1.2 List of Figures 7

2 Introduction 8

  • 2.1 Catalyst 8
  • 2.2 Related Reports 9

3 Market Outlook 11

  • 3.1 Global Markets 11
    • 3.1.1 Forecast 11
    • 3.1.2 Drivers and Barriers - Global Issues 13

4 Current and Future Players 17

  • 4.1 Overview 17
  • 4.2 Trends in Corporate Strategy 19
  • 4.3 Company Profiles 21
    • 4.3.1 Biogen Idec 21
    • 4.3.2 Teva Pharmaceutical Industries 24
    • 4.3.3 Merck Serono (EMD Serono) 27
    • 4.3.4 Sanofi 30
    • 4.3.5 Bayer HealthCare Pharmaceuticals 33
    • 4.3.6 Novartis International 35
    • 4.3.7 Hoffmann-La Roche 38
    • 4.3.8 GlaxoSmithKline 40

5 Appendix 42

  • 5.1 Bibliography 42
  • 5.2 Abbreviations 42
  • 5.3 Methodology 43
  • 5.4 Forecasting Methodology 43
    • 5.4.1 Diagnosed MS patients 43
    • 5.4.2 Percent Drug-Treated Patients 44
    • 5.4.3 Drugs Included in Each Therapeutic Class 44
    • 5.4.4 Launch and Patent Expiry Dates 45
    • 5.4.5 General Pricing Assumptions 46
    • 5.4.6 Individual Drug Assumptions 47
    • 5.4.7 Generic Erosion 50
    • 5.4.8 Pricing of Pipeline agents 51
  • 5.5 Physicians and Specialists Included in This Report 52
  • 5.6 Primary Research - Prescriber Survey 53
  • 5.7 About the Authors 53
    • 5.7.1 Analysts 53
    • 5.7.2 Global Head of Healthcare 54
  • 5.8 About GlobalData 55
  • 5.9 Contact Us 55
  • 5.10 Disclaimer 55

List of Tables

1.1 List of Tables

  • Table 1: Global Sales Forecasts ($m) for Multiple Sclerosis, 2012-2022 12
  • Table 2: Global Multiple Sclerosis Market - Drivers and Barriers, 2012 13
  • Table 3: Key Companies in the Multiple Sclerosis Market, 2012 18
  • Table 4: Biogen's Multiple Sclerosis Portfolio Assessment, 2012 22
  • Table 5: Biogen SWOT Analysis, 2012 23
  • Table 6: Teva's Multiple Sclerosis Portfolio Assessment, 2012 25
  • Table 7: Teva SWOT Analysis, 2012 26
  • Table 8: Merck's Multiple Sclerosis Portfolio Assessment, 2012 28
  • Table 9: Merck SWOT Analysis, 2012 29
  • Table 10: Sanofi's Multiple Sclerosis Portfolio Assessment, 2012 31
  • Table 11: Sanofi SWOT Analysis, 2012 32
  • Table 12: Bayer's Multiple Sclerosis Portfolio Assessment, 2012 34
  • Table 13: Bayer SWOT Analysis, 2012 34
  • Table 14: Novartis' Multiple Sclerosis Portfolio Assessment, 2012 36
  • Table 15: Novartis SWOT Analysis, 2012 37
  • Table 16: Roche's Multiple Sclerosis Portfolio Assessment, 2012 39
  • Table 17: Roche SWOT Analysis, 2012 39
  • Table 18: GlaxoSmithKiline's Multiple Sclerosis Portfolio Assessment, 2012 41
  • Table 19: GlaxoSmithKline SWOT Analysis, 2012 41
  • Table 20: Key Launch Dates 45
  • Table 21: Key Patent Expiries 45
  • Table 22: Physicians Surveyed, By Country 53

List of Figures

1.2 List of Figures

  • Figure 1: Global Market Sales for Multiple Sclerosis by Region, 2012-2022 13
  • Figure 2: Company Portfolio Gap Analysis in Multiple Sclerosis, 2012-2022 20
Back to Top